Literature DB >> 35771310

The P2 purinoceptors in prostate cancer.

Zilin Wang1, Sha Zhu1, Sirui Tan2, Yuhao Zeng1, Hao Zeng3.   

Abstract

P2 purinoceptors are composed of ligand-gated ion channel type (P2X receptor) and G protein-coupled metabolite type (P2Y receptor). Both these receptors have played important roles in the prostate cancer microenvironment in recent years. P2X and P2Y receptors can contribute to prostate cancer's growth and invasiveness. However, the comprehensive mechanisms have yet to be identified. By summarizing the relevant studies, we believe that P2X and P2Y receptors play a dual role in cancer cell growth depending on the prostate cancer microenvironment and different downstream signalling pathways. We also summarized how different signalling pathways contribute to tumor invasiveness and metastasis through P2X and P2Y receptors, focusing on understanding the specific mechanisms led by P2X4, P2X7, and P2Y2. Statins may reduce and prevent tumor progression through P2X7 so that P2X purinergic receptors may have clinical implications in the management of prostate cancer. Furthermore, P2X7 receptors can aid in the early detection of prostate cancer. We hope that this review will provide new insights for future mechanistic and clinical investigations into the role of P2 purinergic receptors in prostate cancer.
© 2022. The Author(s).

Entities:  

Keywords:  Akt; ERK1/2; P2 purinoceptors; P2XR; P2YR; Prostate cancer

Year:  2022        PMID: 35771310     DOI: 10.1007/s11302-022-09874-2

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  34 in total

1.  Structure of the human P2Y₁₂ receptor in complex with an antithrombotic drug.

Authors:  Bing Du; MingYao Liu
Journal:  Sci China Life Sci       Date:  2014-05-06       Impact factor: 6.038

2.  Radiosensitizing Effect of P2X7 Receptor Antagonist on Melanoma in Vitro and in Vivo.

Authors:  Keisuke Tanamachi; Keisuke Nishino; Natsuki Mori; Toshihiro Suzuki; Sei-Ichi Tanuma; Ryo Abe; Mitsutoshi Tsukimoto
Journal:  Biol Pharm Bull       Date:  2017-03-24       Impact factor: 2.233

3.  Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.

Authors:  Iman Azimi; Hannah Beilby; Felicity M Davis; Daneth L Marcial; Paraic A Kenny; Erik W Thompson; Sarah J Roberts-Thomson; Gregory R Monteith
Journal:  Mol Oncol       Date:  2015-09-25       Impact factor: 6.603

4.  Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.

Authors:  Li-Peng Hu; Xiao-Xin Zhang; Shu-Heng Jiang; Ling-Ye Tao; Qing Li; Li-Li Zhu; Ming-Wei Yang; Yan-Miao Huo; Yong-Sheng Jiang; Guang-Ang Tian; Xiao-Yan Cao; Yan-Li Zhang; Qin Yang; Xiao-Mei Yang; Ya-Hui Wang; Jun Li; Gary Guishan Xiao; Yong-Wei Sun; Zhi-Gang Zhang
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

Review 5.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

Authors:  Philip Cornford; Roderick C N van den Bergh; Erik Briers; Thomas Van den Broeck; Marcus G Cumberbatch; Maria De Santis; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikolaos Grivas; Jeremy Grummet; Ann M Henry; Theodorus H van der Kwast; Thomas B Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Lisa Moris; Daniela E Oprea-Lager; Henk G van der Poel; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Thomas Wiegel; Peter-Paul M Willemse; Nicolas Mottet
Journal:  Eur Urol       Date:  2020-10-07       Impact factor: 20.096

Review 6.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Roderick C N van den Bergh; Erik Briers; Thomas Van den Broeck; Marcus G Cumberbatch; Maria De Santis; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikos Grivas; Jeremy Grummet; Ann M Henry; Theodorus H van der Kwast; Thomas B Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Lisa Moris; Daniela E Oprea-Lager; Henk G van der Poel; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Thomas Wiegel; Peter-Paul M Willemse; Philip Cornford
Journal:  Eur Urol       Date:  2020-11-07       Impact factor: 20.096

7.  Extracellular ATP and Purinergic P2Y2 Receptor Signaling Promote Liver Tumorigenesis in Mice by Exacerbating DNA Damage.

Authors:  Isabel Schulien; Birgit Hockenjos; Veerle van Marck; C Korcan Ayata; Marie Follo; Robert Thimme; Peter Hasselblatt
Journal:  Cancer Res       Date:  2019-12-10       Impact factor: 12.701

8.  Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo.

Authors:  Majid Shabbir; Cecil Thompson; Michael Jarmulowiczc; Dimitri Mikhailidis; Geoffrey Burnstock
Journal:  BJU Int       Date:  2008-03-05       Impact factor: 5.588

Review 9.  Cellular rewiring in lethal prostate cancer: the architect of drug resistance.

Authors:  Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2020-03-16       Impact factor: 14.432

10.  Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.

Authors:  Matthew P Deek; Kekoa Taparra; Ryan Phillips; Pedro Isaacsson Velho; Robert W Gao; Curtiland Deville; Daniel Y Song; Stephen Greco; Michael Carducci; Mario Eisenberger; Theodore L DeWeese; Samuel Denmeade; Kenneth Pienta; Channing J Paller; Emmanuel S Antonarakis; Kenneth R Olivier; Sean S Park; Phuoc T Tran; Bradley J Stish
Journal:  Eur Urol Oncol       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.